Much like people with type 1 Gaucher disease (GD), patients with type 3 may be at greater risk…
Articles by Inês Martins, PhD
The effectiveness of ambroxol — a molecule that improves the folding and maturation of abnormal glucocerebrosidase — does not depend only…
The small molecule arimoclomol — which is already in Phase 2/3 clinical testing — improves the folding and maturation of abnormal…
Long-term treatment with Cerdelga (eliglustat), a substrate reduction therapy for Gaucher disease type 1, is safe and…
A Lysosomal Storage Disease Research Program at Massachusetts General Hospital is conducting a survey as part of a study to…
The Parkinson’s Progression Markers Initiative (PPMI) is recruiting people with Gaucher disease for a new study in Parkinson’s…
JScreen, a nonprofit group affiliated with Atlanta’s Emory University, spent October — Gaucher Disease Awareness Month — screening Jewish…
Baebis recently announced that Seeker, the company’s novel newborn screening laboratory platform designed to measure the activity of lysosomal…
Sanofi Genzyme established the Chart Your Own Course scholarship program back in 2013 to help students with lysosomal storage disorders pursue…
Project HOPE has named UnitedHealth Group and the Gaucher Initiative in Egypt the recipients of its 2017 Global Health…